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Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma 
Abstract 
Cutaneous squamous cell carcinoma from the head and neck typically metastasize to the lymph nodes of 
the neck and parotid glands. When a primary is not identified, they are difficult to distinguish from 
metastases of mucosal origin and primary salivary gland squamous cell carcinoma. UV radiation causes 
a mutation pattern that predominantly features cytosine to thymine transitions at dipyrimidine sites and 
has been associated with cutaneous squamous cell carcinoma. In this study, we used whole genome 
sequencing data from 15 cutaneous squamous cell carcinoma metastases and show that a UV mutation 
signature is pervasive across the cohort and distinct from mucosal squamous cell carcinoma. The 
mutational burden was exceptionally high and concentrated in some regions of the genome, especially 
insulator elements (mean 162 mutations/megabase). We therefore evaluated the likely impact of UV-
induced mutations on the dipyrimidine-rich binding site of the main human insulator protein, CCCTC-
binding factor, and the possible implications on CCCTC-binding factor function and the spatial 
organization of the genome. Our findings suggest that mutation signature analysis may be useful in 
determining the origin of metastases in the neck and the parotid gland. Furthermore, UV-induced DNA 
damage to insulator binding sites may play a role in the carcinogenesis and progression of cutaneous 
squamous cell carcinoma. 
Disciplines 
Medicine and Health Sciences 
Publication Details 
Mueller, S. A., Gauthier, M. A., Ashford, B., Gupta, R., Gayevskiy, V., Ch'ng, S., Palme, C. E., Shannon, K., 
Clark, J. R., Ranson, M. & Cowley, M. J. (2019). Mutational Patterns in Metastatic Cutaneous Squamous 
Cell Carcinoma. Journal of Investigative Dermatology, 139 (7), 1449-1458.e1. 
Authors 
Simon Mueller, Marie-Emilie A. Gauthier, Bruce G. Ashford, Ruta Gupta, Velimir Gayevskiy, Sydney Ch'ng, 
Carsten Palme, Kerwin Shannon, Jonathan Clark, Marie Ranson, and Mark Cowley 
This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1433 
 1 
Mutational Patterns in Metastatic Cutaneous Squamous Cell 
Carcinoma 
 
Authors 
Simon A Mueller, MD1,2,3*,   ORCID 0000-0001-9318-7270 
Marie-Emilie A Gauthier, PhD1,2,13* ORCID 0000-0002-5256-9165  
Bruce Ashford, MD1,4,5,6  ORCID 0000-0003-4547-6611 
Ruta Gupta, MD1,78    ORCID 0000-0003-2940-313X 
Velimir Gayevskiy, PhD2  ORCID 0000-0002-2457-6261 
Sydney Ch’ng, MD1,9,10 
Carsten E Palme, MD1,7 
Kerwin Shannon, MD1 
Jonathan R Clark, MD1,7,9  ORCID 0000-0003-1209-772X 
Marie Ranson, PhD5,6,11,   ORCID 0000-0002-5570-9645 
Mark J Cowley, PhD2,12,13  ORCID 0000-0002-9519-5714 
 
* Equal contribution 
 
Affiliations 
1 Sydney Head and Neck Cancer Institute, Chris O’Brien Lifehouse, Sydney, Australia 
2 Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, Australia 
3 Department for Oto-Rhino-Laryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, 
University of Bern, Switzerland  
4 Illawarra and Shoalhaven Local Health District (ISLHD), Wollongong, Australia 
5 School of Biological Sciences, University of Wollongong, Wollongong, Australia 
6 Illawarra Health and Medical Research Institute (IHMRI), Wollongong, Australia 
7 Central Clinical School, The University of Sydney, Sydney, Australia 
8 Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia 
9 Institute of Academic Surgery, University of Sydney, Sydney, Australia 
10 Department of Plastic Surgery, Royal Prince Alfred Hospital, Sydney, Australia. 
11 Centre for Oncology Education and Research Translation (CONCERT), Liverpool, Australia 
12 St Vincent’s Clinical School, UNSW Sydney, Sydney, Australia 
13 Children’s Cancer Institute, Kensington, Australia 
 
Corresponding author 
Simon Andreas Mueller 
Sydney Head and Neck Cancer Institute 
Chris O’Brien Lifehouse 
PO Box M33, Missenden Road 
Camperdown NSW 2050, Australia 
Tel: +61451052718 
Fax: +61295199214  
Email: simon.mueller@insel.ch 
 
 
Study location 
Sydney, New South Wales, Australia 
 2 
Short title 
Mutation patterns in metastatic cSCC 
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ABSTRACT 
Metastases of cutaneous squamous cell carcinoma (cSCC) from the head and neck typically 
occur in lymph nodes of the neck and parotid glands. When a primary is not identified, they 
are difficult to distinguish from metastases of mucosal origin and primary salivary gland SCC. 
Ultraviolet radiation causes a mutation pattern that predominantly features cytosine to 
thymine transitions at dipyrimidine sites and has been associated with cSCC. In this study, we 
used whole genome sequencing data from 15 cSCC metastases and show that a UV-signature 
based on the trinucleotide context of mutations, distinguishable from mucosal SCC, is present 
across the cohort. The mutational burden was exceptionally high and concentrated in some 
regions of the genome, especially insulator elements (mean 162 mutations/Mb). We therefore 
evaluated the likely impact of UV-induced mutations on the dipyrimidine rich binding site of 
the main human insulator protein, CCCTC-binding factor (CTCF), and the possible 
implications on CTCF function and the spatial organization of the genome. Our findings 
suggest that mutation signature analysis may be useful in determining the origin of metastases 
in the neck and the parotid gland. Furthermore, UV-induced DNA damage to insulator 
binding sites may play a role in the carcinogenesis and progression of cSCC.  
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INTRODUCTION 
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer 
(Gurudutt and Genden, 2011) and most primaries arise in the skin of the face and scalp. 
Regional lymph node metastases to the neck and the intraparotid nodes occur in up to 5% of 
patients, entailing significant morbidity and mortality (DʼSouza and Clark, 2011). When 
metastatic squamous cell carcinoma of unknown primary is diagnosed in neck lymph nodes or 
the parotid gland, it is sometimes impossible to determine the primary site based on 
clinicopathologic features alone. The potential tissues of origins include skin, mucosa, or the 
salivary gland.  The few studies using massive parallel sequencing on cSCC demonstrate that 
the variability of affected genes is high and there is extensive overlap with SCC from mucosal 
surfaces, making gene mutation assessment alone an unreliable differentiator (Ashford et al., 
2017; Lawrence et al., 2015; Pickering et al., 2014; South et al., 2014).   
DNA mutation patterns may offer a solution to differentiating skin-derived SCC metastases 
from those originating from other primary sites. Nik-Zainal et al. (2012) demonstrated that 
mutation patterns can be distinguished when considering the region immediately surrounding 
each somatic mutation, that is, the trinucleotide context. The relative contribution of 
recognized mutation signatures can be quantified, providing insights into the exposure of the 
tumor to various mutagenic agents. Since this initial report, a growing number of signatures 
with known associations have been reported (Alexandrov et al., 2018). Ultraviolet radiation 
(UV) is the main risk factor for the development of cSCC and predominantly causes DNA 
mutations at dipyrimidine sites, where it induces CT transitions (Douki and Cadet, 2001; 
Marteijn et al., 2014). Studies using targeted or whole-exome sequencing have observed 
predominance of CT transitions in mostly primary cSCC  (Durinck et al., 2011; Pickering 
et al., 2014; South et al., 2014; Zilberg et al., 2018). Other mutational processes also cause 
CT mutations (Forbes et al., 2017), but trinucleotide mutation signature analysis is able to 
resolve the underlying mutagenic agents, and identify UV-specific CT mutations.  
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The distribution of these mutations is uneven across the genome and affects specific regions 
more than others (Perera et al., 2016). Because of its high dipyrimidine content, the binding 
site of the main human insulator, CCCTC-binding factor (CTCF), is especially susceptible to 
UV-induced mutations. CTCF may play an important role in carcinogenesis, as it regulates 
the transcriptional activity of topologically associated domains (TADs), which represent 
chromatin loops harboring multiple genes (Hnisz et al., 2016; Kemp et al., 2014). 
Here, we analyze genome-wide mutations in regard to their trinucleotide context, present the 
first signature analysis of cSCC metastases and explore its clinical utility. We further assess 
the distribution of UV-induced mutations across the genome, and assess the potential impact 
on CTCF using the approach described by Poulos et al. (2016) in melanoma. 
 
RESULTS 
Patient Characteristics 
Six parotid and nine neck lymph node cSCC metastases from 15 patients were included 
(Table 1). The site of the cSCC primary was unknown in four patients. Two patients received 
immunosuppressive therapy. 
 
Mutational Patterns Across the Genome 
Average coverage of whole genome sequencing (WGS) was 83.0× in tumors and 37.9× in 
blood.  The total number of somatic mutations per sample ranged from 136,105 to 1,423,398 
(mean 638,254; Figure 1a). Mutations occurred mostly in non-coding regions (99.4%), and 
mutation density was 171 times higher for non-coding variants compared to coding variants 
(mean 206.6 vs. 1.2 mutations/Mb, median 168.3 vs. 0.9 mutations/Mb respectively; Figure 
1a and 1b). Assessment of the distribution of somatic mutations across broad genome region 
categories indicated excessive mutation density in insulators (162 mutations/Mb; Figure 1c). 
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The mutations recovered were predominantly CT transitions (average 82.5%, range 76.1% 
to 90.8%; Figure 1d).  
 
Mutation Signature Analysis 
De novo analysis revealed three predominant mutation signatures in our cohort (Signature I, 
II, III; Figure 2a), which clustered with previously reported signatures 7a and 7b (Alexandrov 
et al., 2018; Figure 2b). Signature 7 features predominantly CT mutations, and the sub-
signatures 7a, 7b, 7c, and 7d  are driven by different mutational processes triggered by UV 
exposure (Alexandrov et al., 2018). Signatures 7a and 7b may reflect direct impact of 
photoproducts, while 7c and 7d may represent indirect processes such as erroneous repair 
(Alexandrov et al., 2018). Signatures 7a and 7b were observed in all samples, while 7c and 7d 
were present in four and two cases, respectively (Figure 2c). Signature 32 was strongly 
evident in a single patient (case 06). Signature 58, thought to denote a sequencing artifact, 
was present in seven of the 15 cases (46.7%), and its presence was not associated with tumor 
burden, or the sequencing laboratories.  
Analysis of published whole-exome data of six metastases and 26 primary cSCC (Pickering et 
al., 2014), demonstrated similar dominance of signatures 7a and 7b in both primaries and 
metastases, while the heterogeneity of other contributing signatures was greater than in our 
cohort (Figure 2d). To assess whether the signature pattern allows the distinction of cSCC 
from mucosal SCC, signature analysis on whole-exome data of 44 oral cavity SCC primaries 
from The Cancer Genome Atlas (TCGA; Lawrence et al., 2015) was performed (Figure 2e). 
Most (41 of 44) oral cavity SCC featured a clearly distinct mutation pattern. Two samples 
from the lip (a UV exposed site) and another for which the anatomical location was not 
specified showed similar signatures to our cSCC cohort. 
 
CTCF binding Site Mutations 
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The high prevalence of mutations in insulator regions prompted an investigation of the 
mutational distribution at DNA binding sites of CTCF, the main human insulator protein. We 
applied a strict 13 base pair (bp) motif as previously described (Poulos et al., 2016) (Figure 
3a), excluding three low-confidence bp at both ends of the consensus CTCF binding site 
(CTCFbs) motif of the JASPAR database (Mathelier et al., 2016). The number of recognized 
CTCFbs totaled 5,470. The mutation density at CTCFbs was significantly increased compared 
to their flanking regions (Figure 3b) and mutations were predominantly CT transitions 
(Figure 3c). The average number of mutated motifs per sample was 84.5 per Mb (range 14 to 
223; median 64; IQR 30.5 to 116.5). Across the cohort, a total of 1,404 mutations were 
detected at the 5,470 examined sites, which showed little overlap between patients: 1,026 
(18.8%) motifs were mutated in only one sample, while 219 (4.0%) were mutated in two, 42 
(0.8%) in three, and 22 (0.4%) were mutated over four samples. When regarding both, the 
upper and the lower strand of the DNA, the conserved 13 bp CTCF motif harbors cytosine in 
up to 11 positions (minimum 7) and accounts for up to eight pyrimidine pairs, three of which 
are highly conserved (Douki and Cadet, 2001; Marteijn et al., 2014) (Figure 2a). Throughout 
the cohort, the highest mutation density was detected at dipyrimidine positions 10 and 11 
(Figures 3d, 3e). When we repeated the analysis using control motifs that only match 
positions 8 to 13 of the motif (Poulos et al., 2016), the predilection for mutations in positions 
10 and 11 was nearly eliminated (Figure 3d), proving that it only occurs in the context of a 
conserved CTCFbs.  
The potential impact of the CTCFbs mutations on TADs was then assessed.  From an initial 
4929 TADs identified in normal human epidermal keratinocytes (NHEK) (Rao et al., 2014), 
903 TADs with CTCFbs at both ends were extracted (Figure 4a). Of these, 422 (46.7%) were 
identified to have a mutated CTCF motif in at least one of the delimiting anchor regions 
(across the cohort), and 47 (5.2%) had mutations in both anchor regions. Within the affected 
loops, we detected 1,979 genes, including 38 oncogenes (Liu et al., 2017), 52 tumor 
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suppressor genes (Zhao et al., 2016), and eleven identified as potential tumor drivers (Bailey 
et al., 2018; Table 2). Analysis of a subset (30) of these genes located in the affected TADs  
did not correlate with a change of expression levels between samples that carried the CTCFbs 
mutations and those that did not (Figure S2).  
 
 
DISCUSSION 
Metastases of cSCC Exhibit UV-Induced Mutation Signatures 
This is the first study to apply WGS and signature analysis on metastases of head and neck 
cSCC. Our results confirm that UV-associated mutation signature 7 is present in both cSCC 
primaries and metastases (Figure 2c, 2d), and that the mutation signature pattern clearly 
differs from that of mucosal human papilloma virus (HPV) negative head and neck SCC 
primary lesions (Figure 2e). The mutation analysis of oral cavity SCC was performed on 
primaries, as we are not aware of publicly available data for metastases of mucosal SCC. 
However, we assume that their signatures correspond to those found in metastases, as we have 
shown for cSCC in this study (Figure 2c, 2d). Notably, the TCGA oral cavity SCC cohort 
includes lip tumors (Figure 2e), which are no longer classified as oral cavity SCC by the 
AJCC, but as cSCC as most are solar induced (Amin et al., 2017).   
Thus, algorithmic signature analysis is able to distinguish cSCC metastasis from squamous 
cell carcinoma of different origin. This distinction is impossible based on clinical or histo-
pathological parameters alone, except in the case of HPV positive oropharyngeal SCC 
(Satgunaseelan et al., 2017), and is clinically relevant with regards to prognosis and treatment. 
Four patients in our cohort had no known primary lesion. All four patients were Anglo-celtic 
Australians who had acquired actinic damage to the skin of the head, and mucosal 
examination was unremarkable, making a cutaneous origin of their parotid metastases highly 
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probable. Consistently, UV-signature was strongly present in the tumor tissue of all four 
patients (Figure 2c). Apart from mucosal SCC, signature analysis may also help to distinguish 
cSCC from primary SCC of the salivary gland, an extremely rare entity that is to date a 
diagnosis of exclusion. Many of these presumed primaries may in fact represent metastases 
for which a cutaneous primary was not recognized (Chen et al., 2015), especially in the 
parotid gland. Due to the rarity of this entity and the subsequent lack of published sequencing 
data, its signature profile is unknown, but a significant UV-associated signature is unlikely.  
The predominance of CT transitions is not unique to UV-induced damage, being associated 
with other factors (e.g. ageing processes, alkylating agents exposure), and delivers insufficient 
information to clearly distinguish mutation patterns. Signature analysis based on the 
trinucleotide context overcomes this problem. The extent of the contribution of signatures 
other than UV-signature is variable, and depends on the type of analyzed data. We believe 
that the increased heterogeneity in signatures derived from the whole-exome data of Pickering 
at al. ( 2014) compared to our WGS data (Figure 2c, 2d) is because the great majority of 
mutations in cSCC are located in the non-coding DNA (Figure 1a). Thus, WGS increases the 
power of signature analysis. The publicly available data from Pickering et al. (2014) is 
filtered, which may also have an impact on signatures. Furthermore, the reduced effectiveness 
of repair mechanisms in the non-coding DNA (Budden and Bowden, 2013; Frigola et al., 
2017) may also be reflected in signature analysis of WGS data.  
Consistent with recent work by Inman et al. ( 2018), case 06, who was under azathioprine 
treatment for rheumatoid arthritis, showed strong contribution of signature 32 (Figure 2c). 
Azathioprine increases the risk of skin cancer through inhibition of nucleotide excision repair 
(NER) of UV-induced DNA damage (Coghill et al., 2016). Azathioprine causes a CA bias 
(Zhang et al., 2007), which occurs alongside the UV-induced CT mutations, and is the 
hallmark of Signature 32. Consistently, the rate of CA transitions was more than double in 
case 06 compared to all others (6.89% vs. mean 2.97%, range 1.43 to 4.1%, Figure 1d).   
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UV-induced Mutations at Insulator Sites  
The mutational burden was 171-fold higher in the non-coding regions than in coding regions 
of the genome (Figures 1a, 1b). This concentration may reflect less effective mismatch repair 
in non-coding regions (Frigola et al., 2017) and the higher priority of the transcription coupled 
NER compared to global NER (Budden and Bowden, 2013). The subsequently identified 
concentration of mutations in insulator regions (Figure 1c) may have implications on 
regulatory processes. Considering that a specific tumor driving gene pattern has not yet 
emerged in cSCC, such alternative carcinogenic models are of special interest. We therefore 
assessed the main human insulator CTCF, whose DNA binding site seems prone to UV-
induced damage because of its high cytosine and dipyrimidine content. CTCF simultaneously 
binds to specific base pair sequences at multiple DNA sites, thereby approximating distant 
chromatin regions and forming 3-dimensional DNA loops termed topologically associated 
domains (TADs; Hnisz et al., 2016; Kemp et al., 2014). These can incorporate multiple genes, 
whose expression is dependent on the binding status of CTCF (Holwerda and de Laat, 2013; 
Ong and Corces, 2014; Figure 4b). Loss of CTCF function through mutation of its binding 
site can disrupt TADs and alter the transcriptional activity of the associated genes. This can 
affect the cell phenotype and potentially plays a role in carcinogenesis (Hanssen et al., 2017; 
Hnisz et al., 2016; Kemp et al., 2014; Tang et al., 2015).  
We observed mutated CTCFbs in all 15 cases and the prevalence was considerably higher 
compared to melanoma (Poulos et al., 2016) (mean 84.5 vs. 11.4 mutated motifs/patient).The 
mutation density in the CTCF motif was not only higher than in the flanking region, but 
exceeded the expected concentration based on the high cytosine and dipyrimidine content 
(Figure 3b, 3cc). This clustering of mutations at the CTCFbs was not only previously 
described in melanoma (Poulos et al., 2016), but also in colorectal cancer, which is not UV 
associated (Katainen et al., 2015), and is explained by the fact that bound CTCF blocks access 
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of NER enzymes to the CTCFbs (Sabarinathan et al., 2016). Consistently, cSCC patients with 
dysfunctional NER have comparable mutation density at flanking regions and CTCF motifs 
(Poulos et al., 2016). Interestingly, the two cases in our cohort under treatment with 
immunosuppressants known to inhibit NER, did not exhibit flattening of the mutational peak 
at the CTCFbs (Figure S1). However, this could be explained by the fact that NER is only 
partially deactivated by these immunosuppressants, whereas the impact of XPC-deficiency is 
more deleterious (Budden and Bowden, 2013; Kuschal et al., 2012). Finally, mutations were 
unevenly distributed within the CTCF motif. Strikingly, dypirimidine positions 10 and 11 
comprised the vast majority of all mutations, whereas mutation density was comparably low 
at other dipyrimidine or cytosine positions (Figure 3c, 3d). This is consistent with findings by 
Poulos et al. (2016), who suggest that differential rates of repair at specific motif positions 
cause this asymmetry.  
Assuming that CTCF cannot efficiently bind modified binding sites, mutations potentially 
result in disruption of TADs and dysregulation of their enclosed genes (Figure 4b). Even our 
conservative approach yielded 1,979 genes within 422 affected TADs and included tumor 
suppressor genes and oncogenes. (Table 2). We cannot ascertain at this stage whether the 
identified mutations at CTCFbs contribute to carcinogenesis or are just passenger mutations. 
Using Nanostring technology we did not detect significant changes in expression for genes 
that were located within affected TADs when compared to samples in which the same TAD 
was not affected (total genes tested = 30; Figure S2). However, an adequate determination of 
differential expression would require much larger cohorts (including UV-affected normal 
skin) and gene panels. Poulos et al. ( 2016) reported similar issues even when using RNA-Seq 
in 36 melanoma samples. Nevertheless, they were able to show that expression of cancer-
associated genes in affected TAD loops was statistically different from wildtype TAD loops. 
Ultimately, the assessment of the clinical impact of CTCFbs mutations on gene expression 
and carcinogenesis in cSCC would require functional analysis using patient-derived primary 
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cell cultures. 
 
Conclusion 
Mutation signature analysis has potential future clinical use, as it allows cSCC metastases to 
be distinguished from other SCC when a primary cannot be identified. This is of particular 
value given the absence of uniquely characteristic driver gene mutations in cSCC. An 
alternative mechanism to driver gene mutations in cSCC may lie in UV-induced damage to 
regulatory elements in the DNA, such as the heavily mutated binding site of the insulator and 
master transcription factor CTCF assessed in this study. Functional studies are necessary to 
further explore such possibly carcinogenic models, and future research should therefore also 
be directed to non-coding and regulatory regions of the DNA.  
 
MATERIALS AND METHODS 
Sample Processing and Sequencing 
Patients were prospectively enrolled between March 2015 and July 2017. Informed consent 
and approval from the institutional ethics committee were sought prior to the study 
(UOW/ISLHD HREC 14/397). Samples were snap frozen and underwent histopathology 
review to select areas with high neoplastic content (30-90%).  
DNA was extracted using Qiagen AllPrep DNA/RNA mini Kit (Qiagen, Venlo, Netherlands). 
Quantitation and purity of DNA were measured using NanoDrop spectrophotometry (Thermo 
Fisher Scientific, North Ryde, Australia). DNA integrity was assessed by agarose gel 
electrophoresis and in-house analyses. WGS was performed by Genome.One (Darlinghurst, 
Australia) and Macrogen (Seoul, South Korea) on Illumina HiSeq X to a depth of 30-45X for 
normal and 65-90X for tumor samples. Mapping and variant calling was performed as per 
Tsoli et al. ( 2018). 
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Distribution of Mutations and Signature Analysis 
The distribution of mutations was assessed across broad genome regions using the 
heterochromatin regions, the universal promoter and enhancer DHS datasets from Perera et al. 
(2016), and the CTCF chromatin immunoprecipitation sequencing (ChIPSeq) data for 
insulator regions of NHEK from ENCODE (The ENCODE Project Consortium, 2012). 
From a 96 trinucleotide mutation count matrix, we extracted signatures de novo applying non-
negative matrix factorization (Brunet et al., 2004) using Maftools (Mayakonda and Koeffler, 
2016) in R version 3.5.0 (R Development Core Team, 2008). We also applied the matrix of 
mutational signature weights from Alexandrov et al. ( 2018) to assess similarity and 
coherence of the mutation profiles with recognized signatures usingDeconstructSigs 
(Rosenthal et al., 2016). Signatures were reported when attributable mutations contributed 
>6% in any sample. The same approach was applied on publicly available VCFs from whole-
exome sequencing data of cSCC (Pickering et al., 2014) and oral cavity SCC from TCGA 
(Lawrence et al., 2015). 
 
CTCF Binding Site Mutation Assessment 
To assess mutations at CTCFbs, filtering occurred in two steps to limit false positives, as 
reported by Poulos et al. (2016). First, we selected CTCFbs harboring a strict motif including 
the central 13 bp of the 19 bp consensus motif (Mathelier et al., 2016). Second, we identified 
the sites occurring at ChIP-Seq peaks for CTCF in NHEK available from ENCODE, thus 
assuring that assessed sites have bound CTCF. Binding sites were overlaid with our cohort’s 
WGS data to quantify mutation density at every base in the motif and the neighboring 1kb. 
Results were normalized to mutations per megabase. We repeated the analysis using control 
motifs generated by Poulos et al. (2016) from NHEK ChIP-Seq peaks that only match 
positions 8 to 13 of the motif, while positions 1 to 7 could be any bases other than those 
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observed in CTCF motifs. 
To identify and locate the CTCFbs at boundaries of TADs, we used chromosome 
conformation capture (Hi-C) TAD maps of NHEK (Rao et al., 2014) and ChIP-seq data from 
ENCODE. Hereby, a more permissive 20 bp motif is tolerated, and a 20 bp position weighted 
matrix (Kim et al., 2007) is applied to select for binding sites with high CTCF-binding 
probability. TADs were filtered as illustrated in Figure 4a. TADs were excluded if they had 
more than one CTCF binding motif in either anchor region, and if CTCF motifs were not in 
convergent orientation, since this arrangement has the highest association with binding of 
CTCF (Rao et al., 2014). Genomic coordinates delimitating a TAD were defined as the 3’-end 
of the upstream and the 5’-end of the downstream motif. Genes lying in TADs were identified 
from the UCSC genome browser (Kent et al., 2002) using BEDTools (Quinlan and Hall, 
2010).  
Gene expression analyses 
RNA was extracted using Qiagen AllPrep DNA/RNA mini Kit (Qiagen, Venlo, Netherlands). 
Quantitation and purity of RNA were measured using NanoDrop spectrophotometry (Thermo 
Fisher Scientific, North Ryde, Australia). RNA expression was evaluated by NanoString 
nCounter Sprint system using the PanCancer Progression panel (Nanostring, Seattle, WA, 
USA) as per the manufacturer's instructions. Results were analyzed using NanoString nSolver 
4.0 and Advanced Analysis Module (Nanostring, Seattle, WA, USA), which normalizes gene 
expression to a set of positive and negative controls genes. The expression of genes found in a 
mutated TAD in at least one sample in our cohort was compared to that of the other samples 
of the cohort using a heatmap.  
 
 
 15 
CONFLICT OF INTEREST 
The authors state no conflict of interest. 
 
ACKNOWLEDGEMENTS 
We extend our thanks to Elahe Minaei and Jay Perry of Illawarra Health and Medicine 
Research Institute, Wollongong, Australia, for sample processing, Assistant Prof. Ludmil 
Alexandrov, University of California San Diego, CA, for sharing the updated mutation 
signature matrices, and Associate Prof. Narayanan Gopalakrishna Iyer, National Cancer 
Center Singapore, for conceptual support. MJC is supported by a NSW Health Early-Mid 
Career Fellowship. We thank the Kinghorn Centre for Clinical Genomics for assistance with 
production and processing of whole-genome sequencing data. 
  
 16 
REFERENCES 
Alexandrov L, Kim J, Haradhvala NJ, Huang MN, Ng AWT, Boot A, et al. The repertoire of 
mutational signatures in human cancer. BioRxiv 2018:322859. doi:10.1101/322859. 
Amin MB, Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 
Springer International Publishing; 2017. 
Ashford BG, Clark J, Gupta R, Iyer NG, Yu B, Ranson M. Reviewing the genetic alterations 
in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and 
therapeutic targets. Head Neck 2017;39:1462–9. doi:10.1002/hed.24765. 
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. 
Comprehensive characterization of cancer driver genes and mutations. Cell 2018;173:371–
385.e18. doi:10.1016/j.cell.2018.02.060. 
Brunet J-P, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery 
using matrix factorization. Proc Natl Acad Sci U S A 2004;101:4164–9. 
doi:10.1073/pnas.0308531101. 
Budden T, Bowden NA. The role of altered nucleotide excision repair and UVB-induced 
DNA damage in melanomagenesis. Int J Mol Sci 2013;14:1132–51. 
doi:10.3390/ijms14011132. 
Chen MM, Roman SA, Sosa JA, Judson BL. Prognostic factors for squamous cell cancer of 
the parotid gland: An analysis of 2104 patients. Head Neck 2015;37:1–7. 
doi:10.1002/hed.23566. 
Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madeleine MM. Immunosuppressive 
medications and squamous cell skin carcinoma: nested case-control study within the skin 
cancer after organ transplant (SCOT) cohort. Am J Transplant 2016;16:565–73. 
doi:10.1111/ajt.13596. 
 17 
Douki T, Cadet J. Individual determination of the yield of the main UV-induced dimeric 
pyrimidine photoproducts in DNA suggests a high mutagenicity of CC photolesions. 
Biochemisrty 2001;40:2495–501. doi:10.1021/BI0022543. 
Durinck S, Ho C, Wang NJ, Liao W, Jakkula LR, Collisson EA, et al. Temporal dissection of 
tumorigenesis in primary cancers. Cancer Discov 2011;1:137–43. doi:10.1158/2159-
8290.CD-11-0028. 
DʼSouza J, Clark J. Management of the neck in metastatic cutaneous squamous cell 
carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2011;19:99–105. 
doi:10.1097/MOO.0b013e328343e811. 
Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic 
cancer genetics at high-resolution. Nucleic Acids Res 2017;45:D777–83. 
doi:10.1093/nar/gkw1121. 
Frigola J, Sabarinathan R, Mularoni L, Muiños F, Gonzalez-Perez A, López-Bigas N. 
Reduced mutation rate in exons due to differential mismatch repair. Nat Genet 2017;49:1684–
92. doi:10.1038/ng.3991. 
Gurudutt V V, Genden EM. Cutaneous squamous cell carcinoma of the head and neck. J Skin 
Cancer 2011;2011:502723. doi:10.1155/2011/502723. 
Hanssen LLP, Kassouf MT, Oudelaar AM, Biggs D, Preece C, Downes DJ, et al. Tissue-
specific CTCF-cohesin-mediated chromatin architecture delimits enhancer interactions and 
function in vivo. Nat Cell Biol 2017;19:952–61. doi:10.1038/ncb3573. 
Hnisz D, Weintraub AS, Day DS, Valton A-L, Bak RO, Li CH, et al. Activation of proto-
oncogenes by disruption of chromosome neighborhoods. Science 2016;351:1454–8. 
doi:10.1126/science.aad9024. 
Holwerda SJB, de Laat W. CTCF: the protein, the binding partners, the binding sites and their 
 18 
chromatin loops. Philos Trans R Soc Lond B Biol Sci 2013;368:20120369. 
doi:10.1098/rstb.2012.0369. 
Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, et al. The genomic 
landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational 
signature. Nat Commun 2018;9:3667. doi:10.1038/s41467-018-06027-1. 
Katainen R, Dave K, Pitkänen E, Palin K, Kivioja T, Välimäki N, et al. CTCF/cohesin-
binding sites are frequently mutated in cancer. Nat Genet 2015;47:818–21. 
doi:10.1038/ng.3335. 
Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, et al. CTCF 
haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep 
2014;7:1020–9. doi:10.1016/j.celrep.2014.04.004. 
Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human 
genome browser at UCSC. Genome Res 2002;12:996–1006. doi:10.1101/gr.229102. 
Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, et al. Analysis of 
the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 
2007;128:1231–45. doi:10.1016/j.cell.2006.12.048. 
Kuschal C, Thoms K-M, Schubert S, Schäfer A, Boeckmann L, Schön MP, et al. Skin cancer 
in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp 
Dermatol 2012;21:2–6. doi:10.1111/j.1600-0625.2011.01413.x. 
Lawrence MS, Sougnez C, Lichtenstein L, Cibulskis K, Lander E, Gabriel SB, et al. 
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 
2015;517:576–82. doi:10.1038/nature14129. 
Liu Y, Sun J, Zhao M. ONGene: A literature-based database for human oncogenes. J Genet 
Genomics 2017;44:119–21. doi:10.1016/J.JGG.2016.12.004. 
 19 
Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JHJ. Understanding nucleotide excision 
repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol 2014;15:465–81. 
doi:10.1038/nrm3822. 
Mathelier A, Fornes O, Arenillas DJ, Chen C, Denay G, Lee J, et al. JASPAR 2016: a major 
expansion and update of the open-access database of transcription factor binding profiles. 
Nucleic Acids Res 2016;44:D110–5. doi:10.1093/nar/gkv1176. 
Mayakonda A, Koeffler HP. Maftools: Efficient analysis, visualization and summarization of 
MAF files from large-scale cohort based cancer studies. BioRxiv 2016:052662. 
doi:10.1101/052662. 
Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. 
Mutational processes molding the genomes of 21 breast cancers. Cell 2012;149:979–93. 
doi:10.1016/j.cell.2012.04.024. 
Ong C-T, Corces VG. CTCF: an architectural protein bridging genome topology and function. 
Nat Rev Genet 2014;15:234–46. doi:10.1038/nrg3663. 
Perera D, Poulos RC, Shah A, Beck D, Pimanda JE, Wong JWH. Differential DNA repair 
underlies mutation hotspots at active promoters in cancer genomes. Nature 2016;532:259–63. 
doi:10.1038/nature17437. 
Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, et al. Mutational 
landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 2014;20:6582–
92. doi:10.1158/1078-0432.CCR-14-1768. 
Poulos RC, Thoms JAI, Guan YF, Unnikrishnan A, Pimanda JE, Wong JWH. Functional 
Mutations Form at CTCF-Cohesin Binding Sites in Melanoma Due to Uneven Nucleotide 
Excision Repair across the Motif. Cell Rep 2016;17:2865–72. 
doi:10.1016/j.celrep.2016.11.055. 
 20 
Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. 
Bioinformatics 2010;26:841–2. doi:10.1093/bioinformatics/btq033. 
R Development Core Team. R: A language and environment for statistical computing. R 
Found Stat Comput Vienna, Austria 2008:ISBN 3-900051-07-0, URL http://www.R-
project.org. 
Rao SSP, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A 3D 
map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 
2014;159:1665–80. doi:10.1016/j.cell.2014.11.021. 
Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating 
mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of 
carcinoma evolution. Genome Biol 2016;17:31. doi:10.1186/s13059-016-0893-4. 
Sabarinathan R, Mularoni L, Deu-Pons J, Gonzalez-Perez A, López-Bigas N. Nucleotide 
excision repair is impaired by binding of transcription factors to DNA. Nature 2016;532:264–
7. doi:10.1038/nature17661. 
Satgunaseelan L, Chia N, Suh H, Virk S, Ashford B, Lum T, et al. p16 expression in 
cutaneous squamous cell carcinoma of the head and neck is not associated with integration of 
high risk HPV DNA or prognosis. Pathology 2017;49:494–8. 
doi:10.1016/j.pathol.2017.04.002. 
South AP, Purdie KJ, Watt SA, Haldenby S, den Breems N, Dimon M, et al. NOTCH1 
mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 
2014;134:2630–8. doi:10.1038/jid.2014.154. 
Tang Z, Luo OJ, Li X, Zheng M, Zhu JJ, Szalaj P, et al. CTCF-Mediated Human 3D Genome 
Architecture Reveals Chromatin Topology for Transcription. Cell 2015;163:1611–27. 
doi:10.1016/j.cell.2015.11.024. 
 21 
The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the 
human genome. Nature 2012;489:57–74. doi:10.1038/nature11247. 
Tsoli M, Wadham C, Pinese M, Failes T, Joshi S, Mould E, et al. Integration of genomics, 
high throughput drug screening, and personalized xenograft models as a novel precision 
medicine paradigm for high risk pediatric cancer. Cancer Biol Ther 2018:1–10. 
doi:10.1080/15384047.2018.1491498. 
Zhang X, Jeffs G, Ren X, O’Donovan P, Montaner B, Perrett CM, et al. Novel DNA lesions 
generated by the interaction between therapeutic thiopurines and UVA light. DNA Repair 
(Amst) 2007;6:344–54. doi:10.1016/J.DNAREP.2006.11.003. 
Zhao M, Kim P, Mitra R, Zhao J, Zhao Z. TSGene 2.0: an updated literature-based 
knowledgebase for tumor suppressor genes. Nucleic Acids Res 2016;44:D1023-31. 
doi:10.1093/nar/gkv1268. 
Zilberg C, Lee MW, Yu B, Ashford B, Kraitsek S, Ranson M, et al. Analysis of clinically 
relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. 
Mod Pathol 2018;31:275–87. doi:10.1038/modpathol.2017.128. 
  
 22 
TABLES 
Table 1. Demographic and medical data of the cohort of 15 patients with cSCC lymph node 
metastases. 
Sample Age 
years 
Sex Primary 
location 
Metastasis 
location 
Nodal 
catego
ry 
Tumor 
stage 
LN ratio ECS Grade Immuno-
suppression 
1 30 M Left lip Left neck N3b IV 3/27 Yes 1 No 
2 78 M Right ear Right 
parotid 
N3b IV 2/52 Yes 3 No 
3 74 M Unknown Right 
parotid 
N3b IV 2/42 Yes 3 No 
4 64 M Bilateral 
lip 
Bilateral 
neck 
N2c IV 3/55 No 2 No 
5 78 M Left 
forehead 
Left parotid N2a IV unknown Yes 3 No 
6 69 M Left cheek Left neck N3b IV 4/4 Yes 3 Azathioprine 
7 87 M Unknown Left neck N2b IV 2/42 No 3 No 
8 87 M Unknown Left parotid N3b IV 1/16 Yes 2 No 
9 66 M Bilateral 
forehead 
Right neck N3b IV 2/29 Yes 2 Cyclosporine A, 
Tacrolimus 
10 64 M Left scalp Left neck N3b IV 3/109 Yes 3 No 
11 69 M Unknown Right 
parotid 
N3b IV 2/11 Yes 3 No 
12 77 M Right 
nose 
Right neck N3b IV 3/108 Yes 2 No 
13 77 M Right ear Right 
parotid 
N3b IV 4/64 Yes 2 No 
14 79 F Left cheek Left 
perifacial 
N3b IV unknown Yes 3 No 
15 66 M Left scalp Left scalp N2b IV 2/2 No 2 No 
ECS, extracapsular spread; LN ratio, number of lymph node metastases of total resected lymph nodes 
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Table 2. Genes located in TAD loops with mutated CTCF motifs across the cohort of 15 
cSCC lymph node metastases which are recognized as tumor suppressor genes (TSGene, 
Zhao et al., 2016) oncogenes (ONGene, Liu et al., 2017), or identified as potential tumor 
driver genes (Bailey et al., 2018). 
Tumor-suppressor genes Oncogenes Tumor driver 
genes 
ASCL1 IQGAP2 NOV ASCL1 MALAT1 ZBTB16 CACNA1A 
BASP1 KAT5 ONECUT1 BMI1 MAP3K8 ZEB1-AS1 CARD11 
BMP2 KLF6 PARK2 BOC MFHAS1  DICER1 
BMP4 L3MBTL4 PAX6 CAD MLLT3  ELF3 
CDO1 LEFTY1 PIWIL2 CARD11 NEAT1  IL7R 
CKLF LEFTY2 PLAGL1 CCDC6 NEDD9  KEL 
COPS2 LRIG1 POU6F2 CDC25A NOV  PIK3CA 
CREM MAP3K8 PPARA CKLF NUP214  PLCB4 
CXCL14 MAP4K1 PPP2CA EPS8 PAK7  RAD21 
DCDC2 MAT2A PRDM2 GLI2 PIK3CA  RPS6KA3 
DCLRE1A MIR1226 PRKCE HMGA1 PRKCA  SPTA1 
DICER1 MT1F RASAL1 HSPB1 PRKCE   
EPHB3 MT1G RASAL2 ID2 RAB23   
ESRRB MT1M RUNX2 IL7R SMURF1   
FHIT MT2A SRGAP3 KLF6 STMN1   
FOXO3 NCAM2 ST7 KSR2 TAC1   
GDA NEDD4L ZBTB16 LMO2 TNFRSF1B   
HIVEP1   MAFB TWIST1   
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FIGURE LEGENDS 
Figure 1. Mutation landscape across the cohort of 15 cSCC lymph node metastases. (a) 
Mutation burden per patient in coding and non-coding DNA. (b) Boxplot showing median 
number of mutations per megabase (Mb) in the coding and non-coding DNA. (c) Mutation 
density across different regions of the genome. (d) Distribution at single base level shows 
predominance of CT transitions.  
   
 
Figure 2. Mutation signature analysis. (a) De novo signature analysis of 15 cSCC lymph 
node metastases yielded three distinct signatures based on the contribution of trinucleotide 
context of each mutation. (b) Heatmap showing unsupervised clustering of de novo extracted 
signatures with recognized signatures (Alexandrov et al., 2018). All three de novo extracted 
signatures are most closely associated with UV-associated signatures 7a or 7b. (c) Signature 
profiles of individual samples of the cohort. Signatures contributing less than 6% were 
collapsed.  (d) Signature profiles derived from whole-exome data of 26 cSCC primaries and 5 
lymph node metastases from Pickering et al. ( 2014). (e) Signature profiles derived from 
whole-exome data of 44 oral cavity SCC from TCGA. Signatures contributing less than 8% 
were collapsed.  
  
 
 
Figure 3. Mutational landscape at CTCF binding sites of 15 cSCC lymph node 
metastases. (a) Upper and lower strand nucleic acid sequence showing the conserved center 
of the CTCFbs. Large letters symbolize highly conserved positions. Potential dipyrimidine 
sites are indicated with brackets. (b) Overall density of mutations at merged CTCFbs and 
 25 
neighboring 1000 base pairs. (c) Mutation density and mutation type in the CTCFbs motif and 
flanking 30 base pairs. (d) Mutation density at individual base positions of the CTCFbs 
derived from NHEK ChIP-seq peaks across the cohort showing concentration of mutations at 
position 10 and 11(blue line). The green line illustrates mutation density of a control motif, 
where only positions 8 to 13 match the CTCF motif (A|G)(G|T)GGC(A|G), and positions 1 to 
7 can contain any nucleotide. (e) Mutation density at base positions in individual samples, 
demonstrating the consistency of the distribution of mutations across the cohort.  
 
 
  
Figure 4. CTCF binding sites delimiting topologically associated domains (TADs). (a) 
Workflow for the identification of TADs with mutated CTCF binding sites. (b) Schematic 
illustration of a TAD loop regulated by CTCF. On the left, the TAD is insulated by CTCF 
bound to binding sites located in the anchor regions on both ends of the loop. Binding of 
CTCF enables the adherence of other transcription factors, such as cohesion. A proto-
oncogene lies within the loop, and a downstream enhancer acting on a gene (arrow) is shown. 
On the right, a mutation in one of the CTCFbs (indicated with X) prevents the binding of 
CTCF, thus disrupting the TAD. Consequently, the downstream enhancer now acts on the 
proto-oncogene (dashed arrow). 
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Figure S1. Overall density of mutations at CTCF binding sites and flanking regions. 
(a) Density of mutations in CTCF binding sites and flanking regions of in all 15 samples. 
(b) Density of mutations in CTCF binding sites and flanking regions in a patient treated 
with cyclosporine A and tacrolimus.
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Figure S2. Expression levels of genes in TADs with mutated CTCFbs. Heatmap showing 
expression analysis of 30 genes lying in TADs affected by CTCFbs mutations in at least one of
 15 samples of cSCC lymph node metastasis. Black dots mark samples with affected TADs.  
